172 related articles for article (PubMed ID: 16703516)
21. Decay of HIV type 1 DNA and development of drug-resistant mutants in patients with primary HIV type 1 infection receiving highly active antiretroviral therapy.
Riva E; Pistello M; Narciso P; D'Offizi G; Isola P; Galati V; Turriziani O; Tozzi V; Vincenzi L; Dianzani F; Antonelli G
AIDS Res Hum Retroviruses; 2001 Nov; 17(17):1599-604. PubMed ID: 11779347
[TBL] [Abstract][Full Text] [Related]
22. HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients.
Re MC; Vitone F; Biagetti C; Schiavone P; Alessandrini F; Bon I; de Crignis E; Gibellini D
Clin Microbiol Infect; 2010 Jun; 16(6):640-6. PubMed ID: 19732081
[TBL] [Abstract][Full Text] [Related]
23. Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: latency without on-going cellular infections.
Nunnari G; Otero M; Dornadula G; Vanella M; Zhang H; Frank I; Pomerantz RJ
AIDS; 2002 Jan; 16(1):39-45. PubMed ID: 11741161
[TBL] [Abstract][Full Text] [Related]
24. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
25. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters.
Dybul M; Chun TW; Yoder C; Hidalgo B; Belson M; Hertogs K; Larder B; Dewar RL; Fox CH; Hallahan CW; Justement JS; Migueles SA; Metcalf JA; Davey RT; Daucher M; Pandya P; Baseler M; Ward DJ; Fauci AS
Proc Natl Acad Sci U S A; 2001 Dec; 98(26):15161-6. PubMed ID: 11734634
[TBL] [Abstract][Full Text] [Related]
26. Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy.
Ostrowski SR; Katzenstein TL; Thim PT; Pedersen BK; Gerstoft J; Ullum H
J Infect Dis; 2005 Feb; 191(3):348-57. PubMed ID: 15633093
[TBL] [Abstract][Full Text] [Related]
27. Quantification of HIV-1 proviral DNA in patients with undetectable plasma viremia over long-term highly active antiretroviral therapy.
Debiaggi M; Zara F; Pistorio A; Bruno R; Sacchi P; Patruno SF; Achilli G; Romero E; Filice G
Int J Infect Dis; 2000; 4(4):187-93. PubMed ID: 11231180
[TBL] [Abstract][Full Text] [Related]
28. Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy.
Puthanakit T; Kerr S; Ananworanich J; Bunupuradah T; Boonrak P; Sirisanthana V
Pediatr Infect Dis J; 2009 Jun; 28(6):488-92. PubMed ID: 19504731
[TBL] [Abstract][Full Text] [Related]
29. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
[TBL] [Abstract][Full Text] [Related]
30. Concurrent CMV and EBV DNAemia is significantly correlated with a delay in the response to HAART in treatment-naive HIV type 1-positive patients.
Panagiotakis SH; Soufla G; Baritaki S; Sourvinos G; Passam A; Zagoreos I; Stavrianeas N; Spandidos DA
AIDS Res Hum Retroviruses; 2007 Jan; 23(1):10-8. PubMed ID: 17263627
[TBL] [Abstract][Full Text] [Related]
31. Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children.
Spector SA; Hsia K; Yong FH; Cabral S; Fenton T; Fletcher CV; McNamara J; Mofenson LM; Starr SE
J Infect Dis; 2000 Dec; 182(6):1769-73. PubMed ID: 11069252
[TBL] [Abstract][Full Text] [Related]
32. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy.
Yukl SA; Gianella S; Sinclair E; Epling L; Li Q; Duan L; Choi AL; Girling V; Ho T; Li P; Fujimoto K; Lampiris H; Hare CB; Pandori M; Haase AT; Günthard HF; Fischer M; Shergill AK; McQuaid K; Havlir DV; Wong JK
J Infect Dis; 2010 Nov; 202(10):1553-61. PubMed ID: 20939732
[TBL] [Abstract][Full Text] [Related]
33. Cellular proviral HIV-DNA decline and viral isolation in naïve subjects with <5000 copies/ml of HIV-RNA and >500 x 10(6)/l CD4 cells treated with highly active antiretroviral therapy.
Andreoni M; Parisi SG; Sarmati L; Nicastri E; Ercoli L; Mancino G; Sotgiu G; Mannazzu M; Trevenzoli M; Tridente G; Concia E; Aceti A
AIDS; 2000 Jan; 14(1):23-9. PubMed ID: 10714564
[TBL] [Abstract][Full Text] [Related]
34. HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART.
Lombardi F; Belmonti S; Rapone L; Borghetti A; Ciccullo A; Gagliardini R; Baldin G; Montagnani F; Moschese D; Emiliozzi A; Rossetti B; De Luca A; Di Giambenedetto S
J Clin Virol; 2018 Jun; 103():57-62. PubMed ID: 29656086
[TBL] [Abstract][Full Text] [Related]
35. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
[TBL] [Abstract][Full Text] [Related]
36. Cell-associated HIV-1-DNA quantitation after highly active antiretroviral therapy-treated primary infection in patients with persistently undetectable plasma HIV-1 RNA.
Garrigue I; Pellegrin I; Hoen B; Dumon B; Harzic M; Schrive MH; Séréni D; Fleury H
AIDS; 2000 Dec; 14(18):2851-5. PubMed ID: 11153666
[TBL] [Abstract][Full Text] [Related]
37. Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART.
Sedaghat AR; Siliciano RF; Wilke CO
BMC Infect Dis; 2008 Jan; 8():2. PubMed ID: 18171475
[TBL] [Abstract][Full Text] [Related]
38. Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART.
Sedaghat AR; Siliciano JD; Brennan TP; Wilke CO; Siliciano RF
PLoS Pathog; 2007 Aug; 3(8):e122. PubMed ID: 17784786
[TBL] [Abstract][Full Text] [Related]
39. Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patients.
Paolucci S; Baldanti F; Campanini G; Zavattoni M; Cattaneo E; Dossena L; Gerna G
J Med Virol; 2001 Oct; 65(2):207-17. PubMed ID: 11536225
[TBL] [Abstract][Full Text] [Related]
40. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level.
Viard JP; Burgard M; Hubert JB; Aaron L; Rabian C; Pertuiset N; Lourenço M; Rothschild C; Rouzioux C
AIDS; 2004 Jan; 18(1):45-9. PubMed ID: 15090828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
